Targets › OCT4
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout May 2027.
Transcription factor that binds to the octamer motif (5'-ATTTGCAT-3'). Forms a trimeric complex with SOX2 or SOX15 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206. (UniProt, Q01860)
Open in Phaseline: the race on OCT4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Life Biosciences | ER-100 AAV-based epigenetic therapy delivering OSK transcription factors (OCT4, SOX2, KLF4) via i | OCT4, SOX2, KLF4 | Phase 1 | Open Angle Glaucoma (OAG) | May 2027 |
Open Angle Glaucoma (OAG) (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.